Trial Profile

Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary)
Indications Solid tumours
Focus Adverse reactions
Acronyms VELDAY

Most Recent Events

02 Nov 2017 Results assessing safety, pharmacokinetics effect, biological effects and early clinical evaluation, published in the Investigational New Drugs.
30 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
22 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com